focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
He gets a response from some on here and likes the attention. It's the only attention he has in his life.
He is a nothing. To me he is in a green box too, so he is less than a nothing.
All Frank does is bash companies, so I suspect he is just shorting them. Just take some solace that we are not the only ones that have to read his negative rhetoric.
God! He really hates this company doesn’t he. The question remains. Why waste so much time on something that has no benefit to you whatsoever? It’s like studying for an exam, yet you have no intention of taking said exam.
PS. The Dunning Krueger effect was inspired by Frank.
Dustofnations
"In the real world, trials are often confounded by environmental factors and the lack of continuous data collection on volunteers (e.g. did the patient breathe in some polluted air; did the patient eat something that triggered them; etc). Having a strictly controlled climate and diet controlled environment with continuous biometric monitoring would provide much better datasets!"
They don't keep 'volunteers' in quarantine for life? It's usually a few days. The volunteers, who can be in desperate need of money, eg students, won't keep a running day by day log of whether they breathed in polluted air!!!
My assertion that the business model is questionable remains.
"I also was glad to hear that they're putting the cash into instruments that are achieving a decent yield of 5%+ — like UK Govt gilts or similar"
Really? Gov has huge debt and needs to raise money. There's also a GE this year, which raises uncertainty about direction of govn policy going forward.
Lots of local councils are going technically bankrupt.
Gov gilts are high risk. You can easily get around 4-5% in safer accounts.
Skywalker,
"buoyed by organic growth of 8-10 per cent per year and the contribution from synergistic bolt-on acquisitions."
There you go, backs up exactly as I was saying, revenue growth has slowed significantly.
Where's the significant revenue growth?
The suggestion has been that the company is growing fast, booming etc whereas the figures, revenues and order book, don't back it up.
These are their own figures:
H1 2022
Order: £70m
fy 2022
rev £50.7m
Order £76m
H1 2023
Order: £78m
fy 2023
rev: £56m
Order: £80m
fy 2024
Expected Rev £62m
Great write up from @IChronicle on @hVIVO_UK this week…
✅2023 revenue rises 16 per cent to £56mn for #HVO
✅Adjusted cash profit up 44 per cent to £13mn
✅Net cash of £37mn (5.4p)
✅90% order book coverage for 2024
✅Final dividend of £1.4mn (0.2p)
https://www.investorschronicle.co.uk/ideas/2024/04/09/hvivo-has-strong-upside-potential-even-using-conservative-targets/
An excellent presentation.
I was delighted to have my question about challenge trials for non-infectious disease answered in so much detail by Mo — thanks, Mo, as always. My example was autoimmune diseases such as psoriasis, but Mo also mentioned asthma and allergies.
Ultimately, there is a rich vein of data to be collected by monitoring inflammatory markets and other biometrics in response to therapeutics (and possibly challenges by allergens).
In the real world, trials are often confounded by environmental factors and the lack of continuous data collection on volunteers (e.g. did the patient breathe in some polluted air; did the patient eat something that triggered them; etc). Having a strictly controlled climate and diet controlled environment with continuous biometric monitoring would provide much better datasets!
Mo's answer was, to paraphrase: we're focussing on our core competency of infectious disease for now, but non-infectious challenge trials are a promising area of growth we could branch into in the future.
It was a wonderful answer; it shows forward thinking and planning from the team, yet acknowledges that there's current still plenty of untapped demand in the pathogen-based human challenge trial market to address.
My only minor nit is that I'd have loved a more substantial special dividend on top of the nominal dividend; but let's see what/who they acquire with circa £40m cash.
(p.s. I also was glad to hear that they're putting the cash into instruments that are achieving a decent yield of 5%+ — like UK Govt gilts or similar).
Thanks 91Divoc. Here is an exert from that article:
"However, the rating is modest for a company that is aiming to become a £100mn revenue business by 2028, buoyed by organic growth of 8-10 per cent per year and the contribution from synergistic bolt-on acquisitions.
Offering decent upside to Cavendish’s and Investec’s upgraded target prices of 40p and 41p (from 38p), and the more conservative valuations of Liberum (34.5p) and Stifel (35p), hVIVO’s shares continue to rate a buy."
Why spend so much time on a share in which you don't want to invest.Nor have the balls to go short on. Just go and talk about a share you believe you can make money on.
Great presentation, the company has never looked stronger , a great future ahead ! A PE firms dream !! A couple of contracts signed and we’ll be getting a revenue upgrade later this year …
It’s MO’s turn now.
You are a freak ;-)
MO has huge > 7m options, awarded last year, back dated to 2022 and excersiable from few months time.
He has the incentive to talk up the company.
Look at the conditions attached to his huge 7m options:
"The LTIP has been designed to reward, incentivise and retainMr Khan to deliver sustainable growth for shareholders. The deemed date of award is 24 February 2022, which is the dateMr Khan was appointed CEO. Under the LTIP,Mr Khan has been awarded 7,227,273 nominal cost long term incentive options ("LTIP Options " ) over ordinary shares of £0.001 each in the Company.
Vesting of the LTIP Options is conditional upon a three-year total shareholder return ("TSR") performance against an initial 11p reference price. A portion of the LTIP Options will vest on the third anniversary of the date of award subject to the achievement of a minimum 10% CAGR TSR performance increasing on a straight-line basis to vesting in full subject to the achievement of a 22.5% CAGR TSR performance.
The award of the LTIP Options is also subject to continued employment, malus and clawback provisions and will vest in full on a takeover of the Company."
https://polaris.brighterir.com/public/hvivo/news/rns/story/x21q5mw/export
Personally happy they’re not rushing to use that cash like without being very clear any prospective acquisition is good value and a good fit. Hoping to get a £10m addition to revenues via acquisition as part of the £100m rev target by 2028 so no need to jump in
I wish they'd move along with their acquisitions but I know cathal would be looking to pay bottom dollar. He paid £13m for the whole of Hvivo, which was an insulting amount even at the time! I hope to be on the right side of the deal this time around.
Yep, more meat on the bones as to how they're going to get to £100m by 2028.
I'm always impressed by MO, less so presentationally by Stephen but there's no doubt he knows his stuff too.
Great update from Mo & Stephen, the company is in very safe hands IMHO.
GLA
He is either giggling whilst he posts or he is staring at the screen with a blank expression. Either way he is a sad person. Just be thankful that you are not him. Probably an incel who only has his mum’s phone number in his contacts list.
Don't forget the investor meet presentation at 6pm.
I'm expecting MO will be bullish with vast majority of the presentation similar to the last one.
Let's see if he has anything new to add. Any contracts, given we're already in Q2?
The most loathsome stench of UNquestionable worthlessness
stt1 admit it your an absolute ******* !
They don't mention cash as of 31st March, ie Q1 end.
Given they do mention other post period highlights, I think they should have mentioned the current cash position. Now the new facility is up and running then it would have been useful to see if cash has declined.
All they say is
"Strong cash position underpins the Group's M&A strategy"
Seriously, why does LSE allow this cretin to continue posting? Nothing but a sad disrupter with a grudge because he missed a great opportunity to jump aboard a world leading company with a great future.
Pathetic, him and LSE
Hvo’s price hit 44p on talk and hype (we all know that and got carried away) it over compensated down to 10p and now is moving ahead on the back of profits and cash
Stt 1 - Tly have now soared to 5p which is quite a disaster when you were telling us that they are in a great sector less than 18 months ago and the price was 31p